Moffitt Cancer Center | Strategic Alliance Partners

December 02, 2016

Scott J. Antonia, MD, PhD, chair of the Department of Thoracic Oncology at Moffit Cancer Center, discusses immunotherapies that are emerging in the field of lung cancer.

October 27, 2016

Kosj Yamoah, MD, a radiation oncologist at Moffit Cancer Center, discusses reasons for understanding the racial disparities in patients with prostate cancer. Yamoah shared this insight during an interview at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

October 07, 2016

Jingsong Zhang, MD, PhD, discusses the advancements for patients with metastatic castration-resistant prostate cancer (mCRPC) that have occurred over the last decade.

September 19, 2016

Conor Lynch, PhD, an associate professor of Tumor Biology at Moffitt Cancer Center, discusses the biology of bone metastases in patients with castration-resistant prostate cancer.

September 05, 2016

Richard M. Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer.

September 02, 2016

Peter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.

August 26, 2016

Michael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.

August 26, 2016

Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.

August 26, 2016

Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.

August 25, 2016

Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.

August 25, 2016

Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.

August 24, 2016

Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.

August 24, 2016

Mayer Fishman, MD, discusses the therapeutic landscape in renal cell carcinoma and the next steps needed to further advance the field.

August 23, 2016

Conor Lynch, PhD, sheds light on the biology of bone metastases as well as the mechanism of action for bone-directed therapies for patients with metastatic castration-resistant prostate cancer.

August 22, 2016

Heather Jim, MD, describes the psychological impacts of testosterone-lowering drugs for patients with prostate cancer—and what oncologists should do to help.

August 19, 2016

Peter Johnstone, MD, provides insight on post-prostatectomy radiation therapy for patients with prostate cancer.

August 16, 2016

Mayer Fishman, MD, PhD, medical oncologist, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, professor, Department of Oncologic Sciences and of Internal Medicine, University of South Florida Morsani College of Medicine, discusses the available agents to treat patients with renal cell carcinoma.

June 27, 2016

Morganna Freeman, DO, explains the impact of hedgehog inhibitors in basal cell carcinoma, the ideal patient to receive them, and emerging agents on the horizon for treatment of the disease.

May 27, 2016

Perry Kennedy, PhD, discusses the goals of the RAS Initiative.

April 06, 2016

Jessica Frakes, MD, explains findings from a study that examined treatment and follow-up for HPV-associated oropharynx cancer, and how they could impact clinical practice for the follow-up of patients with the disease.